The aim of this study was to evaluate the pharmacokinetic variations of mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), in both pediatric and adult patients following hematopoietic stem cell transplantation (HSCT). Twenty pediatric patients with a median age of 3 years (range 0.2-12 years) and 13 adult patients with a median age of 54 years (range 18-63 years) were enrolled. Blood samples were collected on days 0, 7, 14, 21, and 30 after allogeneic HSCT. Total and free (unbound) MPA as well as MPA 7-O-glucuronide (MPAG) were quantified using a validated LC-MS/MS assay. The plasma protein binding of MPA and MPAG did not change significantly in pediatric patients over the 1-month sampling period post-HSCT. Howev...
AbstractWe evaluated the pharmacodynamic relationships between mycophenolic acid (MPA), the active m...
With the increasing use of mycophenolic acid (MPA) as an immunosuppressant in solid organ transplant...
Several factors contribute to mycophenolic acid (MPA) between-patient variability. Here we character...
[Purpose] Mycophenolate mofetil (MMF), an ester prodrug of mycophenolic acid (MPA), is widely used a...
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is used to suppress GvHD in patie...
Acute graft-versus-host disease (aGVHD) still remains a major limiting factor following allogeneic s...
Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393Mycophenolate mofetil (MMF), an...
International audienceMycophenolate mofetil (MMF) is an immunosuppressive drug used as a prophylacti...
Mycophenolate mofetil (MMF) is widely used to prevent acute rejection in adults after renal, cardiac...
This review aims to provide an extensive overview of the literature on the clinical pharmacokinetics...
Mycophenolate mofetil (MMF) is an immunosuppressive drug used as a prophylactic agent to prevent acu...
Large between- and within-patient variability has been observed in the pharmacokinetics of mycopheno...
Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil, is an immunosuppressive age...
AbstractA novel approach to personalizing postgrafting immunosuppression in hematopoietic cell trans...
used in organ transplantation to prevent acute rejection. Because MMF can produce hematologic and/or...
AbstractWe evaluated the pharmacodynamic relationships between mycophenolic acid (MPA), the active m...
With the increasing use of mycophenolic acid (MPA) as an immunosuppressant in solid organ transplant...
Several factors contribute to mycophenolic acid (MPA) between-patient variability. Here we character...
[Purpose] Mycophenolate mofetil (MMF), an ester prodrug of mycophenolic acid (MPA), is widely used a...
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is used to suppress GvHD in patie...
Acute graft-versus-host disease (aGVHD) still remains a major limiting factor following allogeneic s...
Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393Mycophenolate mofetil (MMF), an...
International audienceMycophenolate mofetil (MMF) is an immunosuppressive drug used as a prophylacti...
Mycophenolate mofetil (MMF) is widely used to prevent acute rejection in adults after renal, cardiac...
This review aims to provide an extensive overview of the literature on the clinical pharmacokinetics...
Mycophenolate mofetil (MMF) is an immunosuppressive drug used as a prophylactic agent to prevent acu...
Large between- and within-patient variability has been observed in the pharmacokinetics of mycopheno...
Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil, is an immunosuppressive age...
AbstractA novel approach to personalizing postgrafting immunosuppression in hematopoietic cell trans...
used in organ transplantation to prevent acute rejection. Because MMF can produce hematologic and/or...
AbstractWe evaluated the pharmacodynamic relationships between mycophenolic acid (MPA), the active m...
With the increasing use of mycophenolic acid (MPA) as an immunosuppressant in solid organ transplant...
Several factors contribute to mycophenolic acid (MPA) between-patient variability. Here we character...